Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis
- 1 March 1990
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 26 (3) , 345-352
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Role of an early second-look laparotomy in ovarian cancerGynecologic Oncology, 1989
- Second-look procedures in ovarian cancer patients receiving six vs. Nine courses of platinum, adriamycin, cytoxan (PAC) chemotherapy: The SCPMG experience 1982–1985Gynecologic Oncology, 1989
- Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.Journal of Clinical Oncology, 1989
- Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the functional living index—cancerCancer, 1988
- Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.Journal of Clinical Oncology, 1987
- A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.Journal of Clinical Oncology, 1986
- A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group studyCancer, 1986
- Common Epithelial Cancer of the OvaryNew England Journal of Medicine, 1985
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978